Treatment of cardiac arrhythmia via re-expression of TBX5 (gene therapy)

Scientists at the University Medical Center Göttingen found a connection between a reduced expression level of TBX5 and heart failure based on cardiac arrhythmia. The scientists in the group of Prof. Zimmermann were able to develop a gene therapy for the prevention and treatment of a ischemic heart disease and associated complications like cardiac arrhythmia and sudden cardiac death.

Challenge

More than 60% of all deaths due to cardiovascular disease are represented by out-of-hospital Sudden Cardiac Death (SCD). The T-box protein 5 (TBX5) is an essential transcription factor for cardiac development, but it remains unclear whether TBX5 in adult ventricular cardiomyocytes might play an overlooked critical role for cardiac homeostasis.
There is still a medical need for new and effective therapeutic applications for the prevention or treatment of cardiac arrhythmia and SCD.

Our Solution

Discovery: TBX5 protein abundance is significantly reduced in left ventricular biopsies of patients with human ischemic heart disease (ICM) and dilated cardiomyopathies (DCM) when compared to non-failing hearts (Fig.1). In contrast to the common opinion, that TBX5 is most important in the heart muscle, it was found, that the amount of TBX5 especially in the cardiac conduction system plays a critical role for a functioning heart.

Fig.1: Low TBX5 expression level in left ventricular biopsies of ICM & DCM patients. NF: Healthy control, DCM: Dilated cardiomyopathies, ICM: Ischemic heart disease. Control expression: CASQ2: Calsequestrin (calcium-binding protein), GAPDH: Glyceraldehyde 3-phosphate dehydrogenase. Source GB1802864.7

Hypothesis: The decreased expression level of TBX5 in ventricular cardiomyocytes, plays an important role in the adult working myocardium.

Investigation: What is the impact of a TBX5 loss for the cardiac function and what is the therapeutic potential of a normalization of the TBX5 level in vTbx5-KO mice.

Outcome: In mice, a loss of TBX5 expression in the cardiac conduction system results in cardiac arrhythmia, causing a lethality of 50% after 150 days. A re-expression of TBX5 was achieved by inactivation of endogenous inhibitors like microRNA-10a or by enhancing the expression using e.g. CRISPR-dCas9 expression constructs. Enhancing the expression of TBX5 to physiological levels in the cardiac conduction system can be used for prevention of a ventricular heart disease and associated complications such as cardiac arrhythmia and SCD (Fig.2). Latest reulsts point to the assumption, that a treatment can also reverse damage, that was already established.

Fig.2: TBX5 in vivo re-expression in the cardiac conduction system rescues arrhythmia phenotype in ventricular TBX5-KO mouse model. mRNA expression analysis shows physiological re-expression. Statistical analysis shows significantly lower heart rate variability in KO-RE vs KO-CT mice. KO-RE: TBX5 re-expression in vTBX5-KO mice, KO-CT: vTBX5-KO mice control. Source GB1802864.7

Advantages

  • proof-of-concept experiments show that normalisation of the TBX5 expression level is possible in vivo
  • in vTbx5-KO mice a raise of TBX5 expression levels stabilized heart beat rate
  • a first indication for the reversion of an already established damage is found
  • the technology allows for a gene-therapie as a prevention and treatment of cardiac arrhythmia

Applications

New therapeutic application (e.g. gene therapy) for the prevention or treatment of cardiac arrhythmia and sudden cardiac death by TBX5 re-expression to physiological levels.

Development Status

A proof-of-concept for an AAV-based gene therapy was successfully performed (animal model). The inventors are planning experiments to proove this concept in a second animal model and to verify, that already established damage can be reverted.

Patent Status

We have pending patent applications in EP and US. (Applicant: Georg-August-Universität Göttingen public law foundation).

Contact

Dr. Martin Andresen
Patent Manager Life Science
E-Mail: mandresen(at)sciencebridge.de
Reference: BioC-2092-UMG

A subsidiary of